Personalized Risk Information in Cost Effectiveness Studies (PRICES)
Principal Investigator
Name
David Kent
Degrees
MD, MS
Institution
Tufts Medical Center
Position Title
Associate Professor of Medicine
Email
About this CDAS Project
Study
NLST
(Learn more about this study)
Project ID
NLST-47
Initial CDAS Request Approval
Jan 10, 2014
Title
Personalized Risk Information in Cost Effectiveness Studies (PRICES)
Summary
Most of evidence-based medicine is derived from the summary results of clinical trials and other group-based data. It is not surprising then that cost effectiveness estimation is also based on population average incremental costs and benefits. Health care resources, however, are more often allocated through medical decisions made by and for individual patients, who can vary substantially in their probability of benefiting from a given intervention, or in their outcome- or treatment-related preferences. Therefore, the average cost-effectiveness of any intervention may rarely have relevance for clinical decision making, when better personalized information is available.
Responding to a call from the NIH to develop an economic framework for personalized medicine, the Tufts Predictive Analytics and Comparative Effectiveness (PACE) Center and the Center for the Evaluation of Value and Risk, both at Tufts Medical Center, collaborated on a proposal to explore the value of providing clinicians and patients with information regarding each patient's individualized risk of having bad health outcomes so that clinicians can better tailor care.
Responding to a call from the NIH to develop an economic framework for personalized medicine, the Tufts Predictive Analytics and Comparative Effectiveness (PACE) Center and the Center for the Evaluation of Value and Risk, both at Tufts Medical Center, collaborated on a proposal to explore the value of providing clinicians and patients with information regarding each patient's individualized risk of having bad health outcomes so that clinicians can better tailor care.
Aims
A disease simulation model will be developed to determine the optimal strategy in terms of cost-effectiveness for different risk groups of individuals based on participants prescreening risk of lung-cancer death.The NLST data will be utilized to populate the model.
Collaborators
Medical Decision Making research group at the Department of Public Health at Erasmus Medical Center in Rotterdam, The Netherlands.
Related Publications
-
Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V, Cohen JT, van Klaveren D, Soeteman DI, Wong JB, Neumann PJ, Kent DM
Ann. Intern. Med. 2018; Volume 168 (Issue 3): Pages 161-169 PUBMED